Review ArticleIndian Journal of Pharmaceutical Education and ResearchVol. 54 | Issue 4 | 2020 | pp. 865–874Open access
Using Chloroquine and Hydroxychloroquine in the Treatment of COVID-19: Does It Make Sense?
- 1
- 1 Department of Organic Chemistry, Chemistry Institute, Federal University of Bahia, Salvador, Bahia, BRAZIL.
Published in Indian Journal of Pharmaceutical Education and Research
Correspondence: Email: ronbatis@ufba.br
Copyright: © 2020 Manuscript Technomedia. This is an open access article.
- Published:
- Jan 1, 2020
- Received:
- Jul 8, 2020
- Accepted:
- Oct 7, 2020
- DOI:
- 10.5530/ijper.54.4.179
How to cite
Batista, R. (2020). Using Chloroquine and Hydroxychloroquine in the Treatment of COVID-19: Does It Make Sense? Indian Journal of Pharmaceutical Education and Research, 54(4), 865–874. https://doi.org/10.5530/ijper.54.4.179
Abstract
The severe acute respiratory syndrome caused by the new coronavirus SARS-Cov-2 (COVID-19) has quickly turned into a pandemic, infecting more than 10 million people and causing more than 500,000 deaths worldwide. The absence of an effective treatment against this disease has led several researchers to investigate the possibility of redirecting drugs already known to be effective against other diseases in the treatment of COVID-19, among them the antimalarial drugs chloroquine and hydroxychloroquine. This review aims at showing how chloroquine and hydroxychloroquine came to be considered as possible drugs in the treatment of COVID-19 and how the recent in vivo experiments described so far shed light on the adequacy of this use.
Keywords
Subject
Article metadata
| Title | Using Chloroquine and Hydroxychloroquine in the Treatment of COVID-19: Does It Make Sense? |
|---|---|
| Authors | Ronan Batista |
| Affiliations | Department of Organic Chemistry, Chemistry Institute, Federal University of Bahia, Salvador, Bahia, BRAZIL. |
| Corresponding author | ronbatis@ufba.br |
| Journal | Indian Journal of Pharmaceutical Education and Research |
| Volume / Issue | Vol. 54, Issue 4 (2020) |
Also in this issue
- Reduced Pharma Supply Chain in COVID-19: Measures to Reduce India’s Reliance for Active Pharmaceutical Ingredients on China and other Countriespp. 835–842
- Artificial Intelligence: A New Paradigm for Pharmaceutical Applications in Formulations Developmentpp. 843–846
- An Outbreak of Severe Acute Respiratory Syndrome-2019 (COVID-19): A Major Health Concernpp. 847–857
- Pharmaceutical and Biotechnological Importance of Actinobacterial Productspp. 858–864
- The Need for Simulated Patient Method Implementation in Pharmaceutical Education in Polandpp. 875–880